In October 2011, the CCRA released the Report on the State of Cancer Clinical Trials in Canada, which outlined the issues facing cancer clinical trials in Canada and recommendations on how these issues could be resolved. One of the key recommendations was the creation of a pan-Canadian cooperative program to facilitate the initiation and conduct of academic cancer clinical trials in Canada that would link to and build upon the strengths of Canada’s existing clinical trials groups.
In response to the report, the Canadian Cancer Clinical Trials Network (3CTN) was created in 2013 to support a network of institutions that will connect existing clinical trial centres. The overarching goals of the 3CTN are two-fold: (1) to strengthen Canada’s capability and capacity to conduct practice-changing cancer clinical trials developed by the academic sector; and as a result, (2) to improve patient outcomes. Dr. Janet Dancey, Scientific Director leads 3CTN and the Ontario Institute for Cancer Research, NCIC Clinical Trials Group and Network of Networks (N2) are collaborating to function as the 3CTN Coordinating Centre. The Coordinating Centre serves as the administrative hub and provides leadership to the network and program. It also manages the flow of funds from the funding partners to the trial centres to ensure that the skilled human resource infrastructure is in place to undertake a portfolio of multi-centre cancer clinical trials.
3CTN launched its four year business plan in April 2014 and has been developing local regional nodes, networks of centres located across Canada to deliver 3CTN initiatives. For more information, including a list of network sites and initiatives, please visit the 3CTN website.